Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease hepatitis c
Phenotype C0040034|thrombocytopenia
Sentences 27
PubMedID- 25209590 Eltrombopag is a new thrombopoietin receptor agonist which was used successfully in this critical case of thrombocytopenia associated with hepatitis c infection before it became an approved drug for such cases.
PubMedID- 24304453 thrombocytopenia in patients with chronic hepatitis c may represent an obstacle for the initiation of antiviral treatment.
PubMedID- 24128106 [eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis c: two case reports].
PubMedID- 20460556 Objective: to review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (itp) and thrombocytopenia associated with hepatitis c virus (hcv) cirrhosis.
PubMedID- 24714308 Another recent study concluded that anti-p antibodies contribute to thrombocytopenia associated with chronic hepatitis c virus infection [21].
PubMedID- 21188328 The goal of this study is to determine the prevalent mechanism of thrombocytopenia in patients with chronic hepatitis c and the clinical predictors of its severity.
PubMedID- 24653754 In november 2012, the us food and drug administration (fda) approved eltrombopag (promacta), an oral thrombopoietin agonist, for treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of ifn-based therapy.
PubMedID- 20731135 This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis c, including it's role as an adverse event of antiviral therapy.
PubMedID- 24621321 The ifn-α treatment is considered an immune-modulator and increases the risk for immune thrombocytopenia purpura in patients with hepatitis c [10], but the mechanism of ifn-induced autoimmune thrombocytopenia is unclear [10].
PubMedID- 21188204 Chronic hepatitis c infection is associated with thrombocytopenia, and the cause is multifactorial in most patients.
PubMedID- 26417629 Eltrombopag (revolade ) and thrombocytopenia in patients with hepatitis c.
PubMedID- 20805953 The increase in platelet counts after pse may also improve the svr rate in chronic hepatitis c patients with thrombocytopenia [111213].
PubMedID- PMC4034027 Recent reports suggest that certain polymorphisms in type i ifn signaling molecules are associated with ifn-induced neutropenia and thrombocytopenia in patients with chronic hepatitis c. ifnγ binds to a cell-surface receptor composed of two transmembrane polypeptides ifgr1 and ifgr2 resulting in activation of the janus kinases jak1 and jak2, phosphorylation of stat1, formation of stat1 homodimers, and activation of a specific set of genes that encode the effector molecules responsible for mediating its biological activity.
PubMedID- 25728497 Background: there are many potential causes of thrombocytopenia in patients with chronic hepatitis c (chc).
PubMedID- 23671722 Conclusion: attention should be paid to potential thrombocytopenia in the treatment of chronic hepatitis c patients.
PubMedID- 20796207 Epidemiology of thrombocytopenia in patients with chronic hepatitis c: more than meets the eye.
PubMedID- 23001404 Improvement of thrombocytopenia in hepatitis c-related advanced fibrosis patients after sustained virological response.
PubMedID- 20796208 Prevalence of thrombocytopenia among patients with chronic hepatitis c: a systematic review.
PubMedID- 21120192 Suggested that thrombocytopenia in patients with hepatitis c infection may be due to a variety of non-immune and immune mechanisms [28].
PubMedID- 24457056 We report the case of a 51 - year – old caucasian female who developed a severe, reversible, immune thrombocytopenia associated with hepatitis c virus infection.
PubMedID- 19689996 thrombocytopenia in patients with chronic hepatitis c: a possible role of hcv on platelet progenitor cell maturation.
PubMedID- 25331767 Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis c.
PubMedID- 24731162 Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis c patients with thrombocytopenia and advanced fibrosis.
PubMedID- 25764686 thrombocytopenia in patients with chronic hepatitis c represents an obstacle for the initiation of antiviral treatment.
PubMedID- 20720351 A case of severe thrombocytopenia in a patient with chronic hepatitis c caused by a single administration of pegylated interferon alpha 2a subsequent to 48 weeks of pegylated interferon alpha 2b plus ribavirin therapy.
PubMedID- 22312391 However, thrombocytopenia also occurs in patients with chronic hepatitis c without cirrhosis.
PubMedID- 24531177 Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis c virus infection: a new option for clinicians.

Page: 1